Currently, efavirenz (EFV) is widely prescribed as part of antiretroviral therapy (ART) in South Africa, and it is most frequently prescribed in fixed-dose combination (FDC) at a dose of 600 mg.
Efavirenz has been linked to early (two to six weeks1) transient as well as late neuropsychiatric effects, which include increased risk of suicidal ideation,2 encephalopathy,3 catatonia,4 psychosis and ataxia.5,6 All of these have been directly linked to EFV toxicity. The risk for toxicity has been associated with loss of function polymorphisms of cytochrome 2B6, the main metabolising enzyme for EFV.7 It is estimated that about 20% of sub-Saharan Africans are genetically slow metabolisers and may be at risk of EFV toxicity.8
Clinicians should be aware that weight is another factor that predisposes a patient to EFV toxicity, and it is recommended that patients weighing less than 40 kg should be prescribed a reduced dose of 400 mg.5,9 There are no FDCs with a reduced EFV dose available in South Africa, and underweight patients are often over-dosed as healthcare workers often prescribe the FDC with standard doses of EFV.
Efavirenz toxicity should be considered in patients who present with depression, psychosis, catatonia, encephalopathy or ataxia after the first few weeks of therapy when other causes are excluded. These include renal failure, liver failure, vitamin B12 deficiency, syphilis, meningitis and structural brain lesions. Once suspected, it is recommended that EFV be switched to lopinavir or ritonavir. If patients are on first-line tuberculosis medication, the dose of lopinavir or ritonavir needs to be increased, and this can be done over two weeks if gastrointestinal tract (GIT) side effects are a problem.
Healthcare professionals are requested to be vigilant and report any suspected adverse drug reaction (ADR) when using antiretroviral (ARV) drugs. Please complete adverse drug reaction forms when adverse reactions are suspected.
Adverse drug reaction forms can be obtained from the National Department of Health Pharmacovigilance Centre for Public Health Programmes. Any comments and queries can be addressed to the email below:
Tel: +27 (0)12 395 9506/8099
Fax2email: 086 241 2473
Email: npc@health.gov.za
Footnotes
How to cite this article: Dheda M. Efavirenz and neuropsychiatric effects. S Afr J HIV Med. 2017;18(1), a741. https://doi.org/10.4102/sajhivmed.v18i1.741
References
- 1.Puzantian T. Central nervous system adverse effects with efavirenz: Case report and review. Pharmacotherapy. 2002;22:930–933. https://doi.org/10.1592/phco.22.11.930.33624 [DOI] [PubMed] [Google Scholar]
- 2.Mollan KR, Smurzynski M, Eron JJ, et al. Association between efavirenz as initial therapy for HIV-1 infection and increased risk for suicidal ideation or attempted or completed suicide: An analysis of trial data. Ann Intern Med. 2014;161(1):1–10. https://doi.org/10.7326/M14-0293 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 3.Kenyon C, Mfolozi S, Croxford R, Colebunders R, Cohen K. Severe efavirenz-induced vacuolar axonopathy complicated by fatal aspiration pneumonia. Br J Clin Pharmacol. 2012;74(6):1070–1072. https://doi.org/10.1111/j.1365-2125.2012.04299.x [DOI] [PMC free article] [PubMed] [Google Scholar]
- 4.Sabato S, Wesselingh S, Fuller A, Ray J, Mijch A. Efavirenz-induced catatonia. Aids. 2002;16(13):1841–1842. https://doi.org/10.1097/00002030-200209060-00024 [DOI] [PubMed] [Google Scholar]
- 5.Variava E, Sigauke F, Muchichwa P, Maartens G, Martinson N. 2016 Efavirenz toxicity manifesting as cerebellar ataxia: Case series from South Africa. Poster 963 CROI. Dept. of Internal Medicine, Klerksdorp Tshepong Hospital Complex and University of the Witwatersrand, Klerksdorp, South Africa; 2016. [Google Scholar]
- 6.Hauptfleisch MPK, Moore DP, Rodda JL. Efavirenz as a cause of ataxia in children. SAMJ. 2015;105(11): 897–898. https://doi.org/10.7196/SAMJ.2015.v105i11.9451 [DOI] [PubMed] [Google Scholar]
- 7.Desta Z, Saussele T, Ward B, et al. Impact of CYP2B6 polymorphism on hepatic efavirenz metabolism in vitro. Pharmacogenomics. 2007;8(6):547–558. https://doi.org/10.2217/14622416.8.6.547 [DOI] [PubMed] [Google Scholar]
- 8.Nyakutira C, Röshammar D, Chigutsa E, et al. High prevalence of the CYP2B6 516G→ T (* 6) variant and effect on the population pharmacokinetics of efavirenz in HIV/AIDS outpatients in Zimbabwe. Eur J Clin Pharmacol. 2008;64(4):357–365. https://doi.org/10.1007/s00228-007-0412-3 [DOI] [PubMed] [Google Scholar]
- 9.Nemaura T, Nhachi C, Masimirembwa C. Impact of gender, weight and CYP2B6 genotype on efavirenz exposure in patients on HIV/AIDS and TB treatment: Implications for individualising therapy. Afr J Pharm Pharmacol. 2012;6(29):2188–2193. https://doi.org/10.5897/AJPP12.076 [Google Scholar]